Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites
NEW YORK, January 1, 2026, 17:27 ET Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, according to data from healthcare research firm 3 Axis Advisors. The median increase is about 4%, and the figures do not reflect rebates or other discounts. The same dataset showed drugmakers also plan to cut list prices on about nine medicines, including a more than 40% reduction for diabetes drug Jardiance, sold by Boehringer Ingelheim and Eli Lilly, after Medicare negotiated a lower price for 2026. Reuters For investors, that is the opening backdrop for the Eli Lilly